We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Hutchmed (china) Limited | LSE:HCM | London | Ordinary Share | KYG4672N1198 | ORD USD0.10 |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 15.00 | 4.44% | 353.00 | 13,464 | 08:05:34 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 350.00 | 353.00 | 353.00 | 348.00 | 348.00 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | USD 838M | USD 100.78M | USD - | - |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 08:05:34 | AT | 128 | 353.00 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 08/5/2024 | 09:30 | UK RNS | Hutchmed (China) Limited Directorate Change |
| 26/4/2024 | 16:09 | ALNC |  Hutchmed notes CHMP's positive opinion for fruiquintinib approval |
| 26/4/2024 | 13:30 | UK RNS | Hutchmed (China) Limited Positive CHMP Opinion for Fruquintinib |
| 22/4/2024 | 09:30 | UK RNS | Hutchmed (China) Limited Vesting of Awards Under the LTIP |
| 08/4/2024 | 09:30 | UK RNS | Hutchmed (China) Limited 2023 Annual Report and Notice of AGM |
| 05/4/2024 | 09:30 | UK RNS | Hutchmed (China) Limited Data to be Presented at AACR Congress 2024 |
| 02/4/2024 | 10:32 | ALNC | Hutchmed endometrial cancer treatment application accepted for review |
| 02/4/2024 | 07:00 | UK RNS | Hutchmed (China) Limited HUTCHMED and Innovent Announce NDA Acceptance |
| 28/3/2024 | 11:08 | ALNC | Hutchmed lung cancer treatment accepted for review in China |
| 28/3/2024 | 07:00 | UK RNS | Hutchmed (China) Limited Savolitinib sNDA Accepted in China |
Hutchmed (china) (HCM) Share Charts1 Year Hutchmed (china) Chart |
|
1 Month Hutchmed (china) Chart |
Intraday Hutchmed (china) Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 10/5/2024 | 08:00 | (Chi-Med)Hutchinson China Meditech Limited | 4,043 |
| 25/3/2022 | 17:25 | Hutchison Chi-Med (HCM) One to Watch | 3 |
| 23/7/2018 | 10:55 | Hutchison Chi-Med (HCM) One to Watch on Monday | 1 |
| 13/6/2017 | 07:54 | Hutchison China Meditech- CHARTS AND DISCUSSION | 74 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 07:05:34 | 353.00 | 128 | 451.84 | AT |
| 07:01:24 | 350.00 | 665 | 2,327.50 | AT |
| 07:00:46 | 350.03 | 500 | 1,750.15 | O |
| 07:00:40 | 350.00 | 240 | 840.00 | AT |
| 07:00:40 | 350.00 | 2,260 | 7,910.00 | AT |
| Top Posts |
|---|
Posted at 09/5/2024 09:20 by Hutchmed (china) Daily Update Hutchmed (china) Limited is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker HCM. The last closing price for Hutchmed (china) was 338p.Hutchmed (china) currently has 871,256,270 shares in issue. The market capitalisation of Hutchmed (china) is -. This morning HCM shares opened at - |
Posted at 10/5/2024 07:50 by 1jat LaudersThe sales report from Takeda was IMO a very positive one. They reported FY sales of 10.1bn JPY which is approx $65m, with 15m in 2023, that means Pts signed up for $50m in Q1. They are still building the book and have not reached a steady state when new patients are matched by patients coming off the medication. The $50m is approximately adding a net $5m of new sales each month which adds $30m to revenue each quarter in the short term and then the increment will start to tail off as equilibrium is reached. The maths suggests a likely sales trajectory in the US for 2024 Q/ly sales of 50 80 110 140 which totals $380m. We can watch that develop with the HY results at the end of July, but I would be hopeful that Takeda generates $350m of US revenue this year which will bring HCM $50 of royalty payments. EU approval should come in July with sales in the higher volume but maybe price limited markets following…..TH Japan approval around the end of the year with sales starting in 2025. Other markets to follow using these approvals as a base. I can see HCM getting $150-200m in royalty payments in 2026 which will last for a few years. |
Posted at 09/5/2024 09:33 by lauders Wonder why the rise today? Could it be Takeda related? Sales of Fruzaqla.Doubt it is related to the news yesterday: Hong Kong, Shanghai & Florham Park, NJ - Wednesday, May 8, 2024: HUTCHMED (China) Limited ("HUTCHMED" or the "Company") (Nasdaq/AIM: HCM, HKEX: 13) today announces that Dr Renu Bhatia is appointed as an Independent Non-executive Director and a member of Technical Committee of the Company with effect from May 13, 2024. Interesting to see she is the chairman of the Listing Committee of The Stock Exchange of Hong Kong Limited though. |
Posted at 26/4/2024 17:15 by dbadvn US investors so spooked over China that all they are looking at is the money.When the cash starts tocome in they will react. In the meantime HCM remains a huge bargain. |
Posted at 14/3/2024 06:43 by nerdofsteel Excellent share price performance and I admit I sold close to the bottom after years of frustration although did buy 3NVDL on Jan 2nd which is a 3x Nvidia Leveraged ETF so have done extremely well there. I will put some of my profits back into Hutchmed shortly. |
Posted at 12/3/2024 09:43 by 1jat I am not sure these moves on no news really mean anything…and could well be reversed tomorrow when the market takes fright at some statement coming from US/China that indicates more restrictions.The next news I will be looking for will be from Takeda… Their annual results are due in early/mid May and will contain the $15m sales from 2023 disclosed by HCM and the first three months of 2024. There may have been some stocking within the $15m and conversion of those on early access programs, but I hope they can sell $30m in Q1 and build to a $50m/quarter during 2024. This would give US in market sales of $150-180 and a $20m royalty (pure profit) to HCM (plus manufacturing fees). It was interesting to see in the company presentation that Europe is potentially a much larger market than the US. It did not appear that the EMA was giving priority status, so they may take longer than the US to approve…that will also be good news when it comes. |
Posted at 03/2/2024 00:47 by lauders More positive news yesterday and no positive impact on the share price. HCM really are in a rut at the moment. Thought 2024 was going to be better, but still 11 months to go. |
Posted at 30/1/2024 05:03 by lauders Some good news from HCM today.Hong Kong, Shanghai & Florham Park, NJ — Tuesday, January 30, 2024: HUTCHMED (China) Limited (Nasdaq/AIM:H Will it be enough to make the share price + for once? Currently DOWN in HK by 1.88%! |
Posted at 22/1/2024 22:45 by mcmather US closed -7.50%. Will we see any response from the company?There appeared to be support on the US weekly at 14.48ish. Hmmmm. FWIW: "The 55 rating InvestorsObserver gives to HUTCHMED (China) Ltd (HCM) stock puts it near the top of the Drug Manufacturers - Specialty & Generic industry. In addition to scoring higher than 80 percent of stocks in the Drug Manufacturers - Specialty & Generic industry, HCM’s 55 overall rating means the stock scores better than 55 percent of all stocks...Over the past year the S&P 500 has risen 20.68% while HCM has fallen -26.98%" |
Posted at 22/1/2024 08:58 by lauders I know there's not many on his board, but could I suggest copying above link along with a note and sending into the board for airing - if anyone needs contact details I can post here.Already sent an e-mail with the suggestion to ir@hutch-med.com Not sure it will do any good but if we don't try we will never know. The price is really being hit at present. Why though? I suppose, yet again, it is a chance to top-up near 200p, but why do so when the IR/PR is so poor and the share price continues to depress? |
Posted at 14/11/2022 06:58 by lauders Nearly +20% in HK now! Come on HCM share price at least match that! |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
